Welby Inc.
Third Quarter Financial Summary [Japanese GAAP] (Consolidated)
In the nine months ended December 2026 (Q3 consolidated), Welby Inc. reported net sales of 564 million yen (year-over-year increase of 48.4%), operating loss of -371 million yen, ordinary loss of -373 million yen, and net loss attributable to owners of parent of -329 million yen. For the full fiscal year ending December 2026, net sales are projected at 1,466 million yen (130.5% increase year-over-year), with an expected operating loss of -30 million yen. No dividend payment start date. No supplementary presentation materials prepared. There are notes regarding new consolidation scope and accounting treatments.
Key Figures
- Net Sales 564,666 thousand yen (Year-over-Year (YoY) increase of 48.4%)
- Operating Loss -371,938 thousand yen
- Ordinary Loss -373,318 thousand yen
- Net Loss Attributable to Owners of Parent (Quarter) -329,136 thousand yen
- Full-year Net Sales 1,466,000 thousand yen (130.5% increase)
AI要約
Summary of Results
Welby Inc. recorded net sales of 564 million yen for the nine months ended December 2026, representing a significant increase versus the prior year period. However, operating income, ordinary income and net income attributable to owners of parent were in the red. The full-year outlook forecasts net sales of 1,466 million yen (130.5% increase) while projecting an operating loss of -30 million yen. The company continues to invest in new business initiatives and in scaling the PHR platform, incurring investments intended to improve future profitability.
Business Strategy, Investment and Outlook
The company is strengthening its business centered on the PHR platform. To expand product offerings and enhance integrations, Welby Inc. is promoting collaborations with major MyChart/PHR-related corporate clients, municipalities and insurers. In Q3, organizational strengthening measures including capital enhancement and third-party allotment were implemented as part of capital policy. Going forward, the company aims to expand regional medical cooperation, enter new disease areas, and promote model projects for insurers.
Welby Inc.
Company overview · Stock price · Financial data · All IR
